EASL Issues First Clinical Guidance on Resmetirom and Semaglutide for Fatty Liver Disease
Major European liver, diabetes, and obesity societies jointly publish the first framework for selecting and monitoring MASH-targeted drug therapy.
Summary
Three major European medical societies — EASL, EASD, and EASO — have jointly released the first clinical guidance document for using two newly approved drugs, resmetirom and semaglutide, to treat metabolic-associated steatohepatitis (MASH). MASH is a progressive liver disease tied to obesity and metabolic syndrome that can advance to cirrhosis, liver cancer, and transplant need. The guidance outlines which patients qualify — primarily adults with fibrosis stages 2–3, confirmed by non-invasive tests rather than biopsy — and how to choose between the two drugs based on individual patient profiles. Semaglutide is favored for patients with obesity, type 2 diabetes, or cardiovascular disease, while resmetirom suits those without obesity or already on GLP-1 therapy. Both drugs require structured lifestyle support and ongoing monitoring for safety and efficacy.
Detailed Summary
Metabolic-associated steatohepatitis (MASH) is an increasingly prevalent liver disease sitting at the intersection of obesity, insulin resistance, and aging-related metabolic decline. Left untreated, it can progress to cirrhosis, hepatocellular carcinoma, and liver failure — outcomes with serious longevity implications. Until recently, no approved pharmacological options existed. The entry of resmetirom (a thyroid hormone receptor beta agonist) and semaglutide (a GLP-1 receptor agonist) into clinical use marks a turning point for the field.
This joint guidance from EASL, EASD, and EASO synthesizes current evidence and regulatory approvals to provide clinicians with practical recommendations. The document covers patient selection, drug initiation, monitoring protocols, and discontinuation criteria — filling a critical gap left by the speed of regulatory approval outpacing clinical consensus.
For patient selection, the guidance recommends pharmacotherapy in adults with non-cirrhotic MASH and fibrosis stages 2–3, confirmed via non-invasive tests such as vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), or the enhanced liver fibrosis (ELF) score, removing the historical requirement for liver biopsy in most cases. This represents a significant practical shift in clinical workflow.
Drug selection is individualized: semaglutide at 2.4 mg subcutaneously weekly is preferred for patients with obesity, type 2 diabetes, or established cardiovascular disease, given its proven cardiometabolic benefits beyond the liver. Resmetirom at 80 or 100 mg orally daily is prioritized for patients without obesity or those who cannot tolerate GLP-1 receptor agonists. Both agents should be used alongside structured lifestyle intervention and optimized management of comorbidities.
Neither drug is currently recommended for MASH patients who have already progressed to cirrhosis, as long-term liver-specific benefit data remain pending. Monitoring for sarcopenia and nutritional status is specifically flagged for patients on semaglutide. This guidance represents a landmark step toward evidence-based, personalized treatment of a disease that is projected to become a leading cause of liver transplant in aging populations.
Key Findings
- Resmetirom or semaglutide are now recommended for adults with MASH and fibrosis stages 2–3 confirmed by non-invasive testing.
- Semaglutide is preferred when obesity, type 2 diabetes, or cardiovascular disease coexist, due to its cardiometabolic benefits.
- Resmetirom is prioritized in patients without obesity or those intolerant to GLP-1 receptor agonists.
- Non-invasive fibrosis tests (VCTE, MRE, ELF) can replace liver biopsy for treatment eligibility decisions.
- Neither drug is recommended as MASH-targeted therapy in patients with cirrhosis until more data are available.
Methodology
This is a joint clinical guidance document issued by EASL, EASD, and EASO, not a primary research study. It synthesizes existing clinical trial evidence and regulatory approval data for resmetirom and semaglutide to produce consensus-based recommendations. Recommendations are graded according to available evidence and expert consensus from three major specialty societies.
Study Limitations
This summary is based on the abstract only; the full guidance document was not available for review. The guidance is primarily European in regulatory scope and may not fully align with FDA-approved indications or US clinical pathways. Long-term MALO outcome data for both drugs in MASH remain pending from ongoing trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: